{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-026840","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.939414+00:00","generated_at":"2026-06-12T06:06:22.703494+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AgeX amends convertible notes with Juvenescence; deadline for reverse financing extended to Oct 31","bullets":["Juvenescence deadline for Reverse subsidiary's >$15M financing extended to Oct 31, 2023 (from prior date).","Juvenescence may convert outstanding amounts without 19.9% cap if conversion price equals Drawdown Market Price.","$10M Secured Note principal exchanged for Series B Preferred stock; ~$692,800 of accrued fees remain convertible.","AgeX drew $500,000 under amended Secured Note on Aug 1, 2023; repayment due Feb 14, 2024.","Conversion of $10M Note allowed until Oct 31, 2023; after that, only after qualified merger or Mar 13, 2024 (plus 90 days)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-026840","json":"https://secwatch.observer/filing/0001493152-23-026840.json","markdown":"https://secwatch.observer/filing/0001493152-23-026840.md","text":"https://secwatch.observer/filing/0001493152-23-026840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223026840/0001493152-23-026840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223026840/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T06:06:22.703494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"311af0a2415cd86c6ddc672a15f87c62476fe2e9","claim":"Serina Therapeutics, Inc. incurred credit facility of $500,000 with Juvenescence Limited maturing February 14, 2024.","evidence_excerpt":"On August 1, 2023, AgeX drew $500,000 of its credit available under the Secured Note as amended by the Fourth Amendment.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223026840/0001493152-23-026840-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$500,000"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Maturity","value":"February 14, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"82c42503eb63ff8b2c38e0ef183c57cb57905b69","claim":"Serina Therapeutics, Inc. entered into Fourth Amendment to the Amended and Restated Secured Convertible Promissory Note with Juvenescence Limited valued at extended Reverse Financing Condition deadline to October 31, 2023; Juvenescence may convert without (effective 2023-07-31).","evidence_excerpt":"On July 31, 2023, AgeX and Juvenescence Limited (“Juvenescence”) entered into a Fourth Amendment (the “Fourth Amendment”) to the Amended and Restated Secured Convertible Promissory Note (the “Secured Note”) to provide that (i) the definition of Reverse Financing Condition is amended to extend to October 31, 2023 the referenced deadline for fulfillment of the condition to permit borrowing or other incurrence of indebtedness by AgeX’s subsidiary Reverse Bioengineering, Inc., and (ii) Juvenescence may convert the outstanding amount of the Secured Note loans or any portion of such loans into AgeX common stock without restriction by the “19.9% Cap” if Juvenescence elects to convert those amounts at a conversion price or prices equal to the “Drawdown Market Prices” applicable to such loan amounts in lieu of a lower conversion price set with reference to the current market price of AgeX common stock at the time of conversion.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000149315223026840/0001493152-23-026840-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Juvenescence Limited"},{"label":"Value","value":"extended Reverse Financing Condition deadline to October 31, 2023; Juvenescence may convert without"},{"label":"Effective","value":"2023-07-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}